Indirect data suggest oral semaglutide outperforms orforglipron on weight loss and tolerability, with patients also favoring its treatment profile.

Invesco S&P 500 Revenue ETF (RWL) offers differentiated large-cap exposure by revenue weighting, reducing mega-cap and ...

The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit ...

When it comes to price performance, XME is a clear winner on a longer time frame, while underperforming REMX on a 1-year ...

GLP-1s are linked to a broad range of adverse events — largely gastrointestinal, metabolic, and psychological — across ...

New free platform analyzes any US address for EV charger viability using federal data, AI-powered insights, and ...

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

Phase 1 data suggest that WVE-007, an investigational siRNA drug given by injection, leads to reductions in visceral fat, waist circumference, and body weight.

CLEVELAND, Ohio — More people are taking GLP-1 drugs like Ozempic, Wegovy and Mounjaro to lose weight and control Type 2 ...

This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, ...

Wave Life Sciences' shares dropped after its weight loss candidate failed to impress in a phase 1 study. However, this ...

The weight-loss drug market is surging, with biotech firms racing to win share in a sector dominated by Novo Nordisk and Eli ...